Comparative Pharmacology
Head-to-head clinical analysis: ERTAPENEM SODIUM versus MERREM IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERTAPENEM SODIUM versus MERREM IV.
ERTAPENEM SODIUM vs MERREM IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. It is a carbapenem antibiotic with broad-spectrum activity against Gram-positive and Gram-negative aerobes and anaerobes.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1 g IV or IM once daily.
1 g intravenously every 8 hours over 15-30 minutes for complicated intra-abdominal infections; 500 mg intravenously every 8 hours for complicated skin and skin structure infections.
None Documented
None Documented
Terminal half-life: ~4 hours (range 3.5-5.3) in young adults; prolonged in renal impairment (e.g., ~7.5 hours in moderate impairment, ~13 hours in end-stage renal disease)
Terminal elimination half-life approximately 1 hour in adults with normal renal function; prolonged to 4–6 hours in moderate renal impairment and up to 10 hours in severe impairment; clinical context: dosing interval adjustment required for CrCl <50 mL/min.
Renal: ~80% unchanged in urine; fecal: ~10% as metabolites; biliary: minimal (<1%)
Primarily renal (approximately 70% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for ~20% as microbiologically inactive metabolite; minimal nonrenal clearance.
Category A/B
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic